Aim and Objectives To analyse the impact of inadequate empirical therapy (IAT) on mortality in patients with Pseudomonas aeruginosa (PA) infection in a tertiary hospital.
Material and Methods Observational, retrospective study of patients with PA infection and treated with previous empirical antipseudomonal antibiotics from 1 January 2021 to 31 October 2021. Variables: gender, age, place of admission, dosing regimen, primary focus of infection and mortality during admission or 30 days after discharge. Definition of IAT: non-adherence to the local guidelines that establish the new EUCAST 2021 dosing criteria to achieve sufficient levels of antibiotics reported as 'sensitive with increased exposure' and which, based on the prevalence of multi-resistance in PA, recommends empirical use with biotherapy until the antibiogram is available. Data source: pharmacotherapeutic management softplante (Farmatools®) and electronic medical records. Analysis with SPSS Statistics21®
Results 92 patients were admitted to ICU and 126 to non-ICU (men 67.4% and 69.8% respectively) with a mean age of 62.9±12.5 years in ICU and 71.4±15.3 in non-ICU.

In the ICU the main source of infection was the lung (48.9%), while in the non-ICU the lung and urinary tract were at the same level (29.4% each).

In both groups the use of β-lactams (76.8% ICU and 65.7% non-ICU), followed by aminoglycosides in the ICU (13.5%) and quinolones in the non-ICU (22.5%). The use of monotherapy was higher in the non-ICU than in the ICU (66.9% vs. 49.2%, p<0.001).

The IAT was higher in the non-ICU (67.5% vs. 47.8% ICU p=0.041). In non-ICU, the mortality rate during admission or at 30 days in patients with IAT was 22.4% vs 7.3% with adequate empirical therapy (OR: 3.64; 95% CI 1.01–13.13), this difference being statistically significant. In ICU there were also higher mortality rates in the IAT group (50.0% vs 39.6%), but without statistically significant differences (OR:1.53; 95% CI 0.67–3.49).
Conclusion and Relevance The higher mortality observed in cases of IAT implies the need to work on the adequacy of dosage according to EUCAST criteria and to promote bitherapy until the antibiogram is available.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Conflict of Interest No conflict of interest.

4CPS-005 DRUG PERSISTENCE OF JAK INHIBITORS COMPARED TO BIOLOGIC DRUGS IN REAL-WORLD PRACTICE IN PATIENTS WITH RHEUMATOID ARTHRITIS

[1]P Llopis-Salvia*, [1]M Saez-Bello, [1]D Viedma-Rama, [1]M Hermenegildo-Caudevilla, [2]JJ Alegre-Sancho, [1]M Climente-Marti. *[1]Hospital Universitario dr Peset, Pharmacy, Valencia, Spain; [2]Hospital Universitario dr Peset, Rheumatology, Valencia, Spain*

10.1136/ejhpharm-2024-eahp.109

Background and Importance JAK-inhibitors (JAKi) represent an effective choice for patients diagnosed with rheumatoid arthritis (RA). There is limited data available on real use of JAKi.
Aim and Objectives To compare persistence of JAKi, TNF-α inhibitor(TNFi) and non-TNF-α inhibitor(non-TNFi) drugs in patients with RA and reasons for treatment discontinuation.
Material and Methods An ambispective, observational study conducted at a tertiary hospital. Patients diagnosed with RA evaluated at the Rheumatology Interdisciplinary Committee of Biological Drugs from 1 January 2018 to 7 January 2022 that started or switched treatment with JAKi, TNFi and non-TNFi were included. Treatments previously received were included. Follow-up was carried out until 7 January 2023.

Variables collected were age, sex, type of drug, prior biologics (naïve, second-line and third- or higher line), patient's chronicity level according to the Chronicity Strategy of Valencian Community (0 =healthy individual to 4 = chronic patient of high complexity), length of treatment and reasons for discontinuation.

Outcome variable was percentage of treatments that reached 12 months persistence estimated from the first to the last drug dispensation.

Data were collected from the electronic health and pharmacy dispensing records.

Continuous variables were expressed as mean (SD), and categorical variables as absolute and relative frequency. Chi-square test and logistic regression were used to identify variables associated with persistence. Statistical significance was set at p<0.05. Analysis was carried out with R-4.3.1.
Results There were a total of 303 patients (75% women), mean age was 53 (16) years. We recorded 623 treatments: JAKi 156 (25.0%), TNFi 326 (52.4%) and non-TNFi 156 (22.6%).

Chronicity level (n=177 (58.4%) patients) was: '0' 40 (11.7%), '1' 143 (41.7%), '2' 109 (31.8%), '3' 51 (14.8%). Treatment line: first 284 (45.6%), second 146 (23.4%) and third or higher 193 (31.0%).

No difference in persistence was found among JAKi 108 (69.2%), TNFi 215 (66%) and non-TNFi 80 (56.7%) treatments (p=0.06). Treatment line showed persistence differences: naïve 213 (75%), second-line 81 (55.5%) and third -or higher 109 (56.5%) (p<0.01). No difference was found in persistence according to sex, age or chronicity level. Multivariate analysis confirmed these results.

At the end of follow-up 460 (73.8%) treatments had finished due to: 199 (43.3%) secondary failures; 100 (21.7%) adverse effects; 74 (16.1%) primary failures and others 50 (18.9%). No differences were found among according to type of therapy (p=0,48).
Conclusion and Relevance In our hospital 12-months' persistence and reasons for discontinuation among JAKi, TNFi and non-TNFi in patients with RA showed no difference.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Conflict of Interest No conflict of interest.

4CPS-006 ADHERENCE TO NEBULISED ANTIBIOTICS IN CYSTIC FIBROSIS PATIENTS AFTER STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR

[1]F Martínez de la Torre*, [2]L Diab Caceres, [1]B Bertran De Lis Bartolome, [1]M Gonzalez sevilla, [1]MD Canales Siguero, [1]MDC Jimenez Leon, [1]F Mayo Olveira, [1]A Castro Frontiñan, [1]A Gonzalez Gomez, [1]JM Ferrari Piquero. *[1]Hospital Universitario 12 de Octubre, Pharmacy, Madrid, Spain; [2]Hospital Universitario 12 de Octubre, Pneumology, Madrid, Spain*

10.1136/ejhpharm-2024-eahp.110

Background and Importance Elexacaftor/tezacaftor/ivacaftor (ETI) are bringing about a major change in the treatment of cystic fibrosis (CF) patients. However, continuing with other treatments such as nebulised antibiotics is necessary.
Aim and Objectives To assess the adherence to inhaled antibiotics before and after starting ETI. Secondary objectives: To assess effectiveness of ETI.